December 9, 2011
At a press seminar held in Tokyo on December 7, Kenya Shitara, director of the Intellectual Property Department, Kyowa Hakko Kirin, revealed that Kyowa Kirin is conducting research with ribonucleic acid interference (RNAi) drugs for practical use by using drug...read more